We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Stents Deliver Gene Therapy to Heart Vessels

By HospiMedica staff writers
Posted on 16 Jan 2006
Stents coated with a compound that binds in an extremely thin layer to bare metal surfaces could be used to deliver therapeutic genes to target cells in heart arteries.

Researchers at the children's hospital of Philadelphia (Philadelphia, PA, USA) have developed a novel technique to attach therapeutic genes to a stent's bare metal surface. More...
This technique could allow the genes to help heal the arteries surrounding the heart while avoiding the inflammation caused by polymer coatings. The study results were published in the December 2005 early edition of the Proceedings of the [U.S.] National Academy of Sciences.

The unique water-soluble compound, polyallylamine biphosphonate, binds to the stent's metal alloy surface in a layer with the thickness of only a single molecule. The biphosphonate holds and gradually releases adenovirus particles of the type used to deliver therapeutic genes. The researchers used a therapeutic gene that encodes inducible nitric oxide synthase (iNOS), a protein in the carotid artery, because of iNOS's ability to control cell damage in blood vessels.

In cell cultures, the adenovirus successfully delivered genes from alloy samples to animal arterial smooth muscle cells. In a second experiment using rodents, the researchers detected gene expression with significantly lower restenosis in the carotid arteries of animals with the experimental stents, compared to control animals with conventional, polymer-coated stents.

"This is the first study to demonstrate successful delivery of a gene vector from a bare metal surface,” said senior author Dr. Robert J. Levy, the William J. Rashkind chair of pediatric cardiology at the children's hospital of Philadelphia. "However, in further studies, one might use a combination of therapeutic genes or different gene vectors, for even better results.”





Related Links:
Children's Hospital of Philadelphia

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.